Boston Scientific faces earnings uncertainty after cybersecurity incident; Wells Fargo cuts price target.

Boston Scientific's earnings outlook for 2026 has become uncertain following a cybersecurity incident that disrupted its operations. Wells Fargo lowered its price target from $50 to $48 but maintained an Equal Weight rating, indicating cautious optimism with about 7.6% upside potential. While brokerage recommendations were generally positive earlier in September, Zacks issued a bearish earnings-based rank later in the month. This mix of analyst views reflects the challenges in valuing the company amid the recent operational setback.

Boston Scientific's recent cybersecurity issues add to the cautious atmosphere around its stock. On Pluang, BSX trades at USD 44.76, showing a modest 0.31% gain as of September 24, 2026, 20:24 WIB. Despite the operational challenges, the stock remains closer to its 52-week low of USD 42.63 than the high of USD 104.98, with a market cap of $64.66 billion and a typical hold time of 77 days, while most Pluang users are currently selling the stock (92% sell orders).